2 results
Approved WMOCompleted
PRIMARY* To determine the efficacy on study Day 28 of T-Guard in inducing a clinical response in patients with severe acute GVHD refractory to first line steroid therapy.SECONDARY* To evaluate the overall safety and efficacy during the first 6…
Approved WMOWill not start
The primary objective is to test the hypothesis that post-MI diabetic patients with relatively preserved ejection fraction of 36-50% will have a survival benefit from a subcutaneous implantable cardioverter defibrillator (S-ICD).